Blog
RSS FeedPosted by Michael Wonder on 08 Mar 2023
NICE recommended weight loss drug to be made available in specialist NHS services
8 March 2023 - Thousands of people will soon be able to be prescribed a drug to help them lose weight ...
Posted by Michael Wonder on 07 Mar 2023
PHARMAC funds two new treatments for lung cancer
7 March 2023 - PHARMAC has announced the funding of two new medicines - pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for people ...
Posted by Michael Wonder on 07 Mar 2023
DoH makes further tweaks to the agenda for this week's PBAC meeting
7 March 2023 - We are now at version 4 with four revisions. ...
Posted by Michael Wonder on 06 Mar 2023
Will reimbursement criteria of SMA treatment Spinraza change?
6 March 2023 - The discussion will likely begin in earnest this month to expand reimbursement criteria for Spinraza (nusinersen ...
Posted by Michael Wonder on 05 Mar 2023
Our progress in the funding of medicines for rare disorders
3 March 2023 - PHARMAC will hear from people affected by rare disorders in its upcoming Rare Disorders Advisory Committee meeting ...
Posted by Michael Wonder on 05 Mar 2023
Medicine and medical device pricing and reimbursement in Netherlands
2 March 2023 - Since the Netherlands is a Member State of the European Union, it has implemented the European ...
Posted by Michael Wonder on 03 Mar 2023
Public Summary Documents – November 2022 PBAC meeting (round 1)
3 March 2023 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the November 2022 PBAC ...
Posted by Michael Wonder on 03 Mar 2023
DoH tweaks the agenda for next week's PBAC meeting (2023/1)
3 March 2023 - We are now up to version 3; six revisions including two withdrawn submissions. ...
Posted by Michael Wonder on 03 Mar 2023
PHARMAC releases final response to review
3 March 2023 - "There are 30 actions we committed to in the interim response – these are part of ...
Posted by Michael Wonder on 02 Mar 2023
Efficient RCTs with real world data for benefit assessments: accelerating evidence-based care
2 March 2023 - Together with colleagues from the Belgian HTA agency KCE, three employees of IQWiG in the BMJ are ...
Posted by Michael Wonder on 02 Mar 2023
Asfotase alfa for the treatment of certain patients with paediatric-onset hypophosphatasia
1 March 2023 - This evaluation reviews the evidence for asfotase alfa for the treatment of patients with paediatric‑onset hypophosphatasia (HST6), ...
Posted by Michael Wonder on 01 Mar 2023
ICER publishes evidence report on lecanemab for Alzheimer’s disease
1 March 2023 - Currently available evidence is rated as promising but inconclusive to determine whether lecanemab provides a net health ...
Posted by Michael Wonder on 01 Mar 2023
Eight digitally enabled therapies to treat depression and anxiety in adults conditionally recommended by NICE
1 March 2023 - Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by ...
Posted by Michael Wonder on 01 Mar 2023
Eptinezumab for the prevention of migraine
1 March 2023 - The recommendation was made after consideration of the evidence submitted by Lundbeck, a review of this submission ...
Posted by Michael Wonder on 28 Feb 2023
Baricitinib for the treatment of patients with severe alopecia areata
28 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...